Each week the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Pharmaceutical company Daiichi Sankyo made a $10m pledge yesterday to Hatch Biofund 1, a US-based venture capital fund formed by non-profit medical research organisation Baruch S. Blumberg Institute. Hatch Biofund has a $50m target for its close, and Daiichi Sankyo’s commitment was made in connection with a collaboration agreement with life sciences incubator Pennsylvania Biotechnology…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.